Related Experiment Video
Updated: Mar 6, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.5K
First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease
M Senek1, M Hellström1, J Albo2
1Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden.
Acta Neurologica Scandinavica
|March 17, 2017
Summary
Individualized levodopa/carbidopa microtablets improved treatment for some Parkinson's disease patients, with a user-friendly dose dispenser aiding adherence. Further research is recommended to confirm these findings.
Area of Science:
- Neurology
- Pharmacology
- Medical Devices
Background:
- Levodopa is a primary symptomatic treatment for Parkinson's disease (PD).
- Disease progression necessitates individualized and finely-tuned treatment strategies.
- Optimizing drug delivery is crucial for managing PD symptoms.
Purpose of the Study:
- To assess the efficacy and patient-perceived usability of individualized levodopa/carbidopa dosing.
- To evaluate microtablets administered via a dose dispenser for Parkinson's disease management.
Main Methods:
- Retrospective review of patient records and dose dispenser data.
- Patient questionnaires assessing treatment effect and usability.
- Analysis of adherence data from dose dispenser reports.
Main Results:
- Six out of nine patients reported improved treatment effects.
- One-third experienced improved bradykinesia; troublesome dyskinesia varied.
- Dose dispenser adherence was high at 97(±5)%.
- Usability of the microtablet system was generally rated as good.
Conclusions:
- Microtablets may enhance treatment outcomes for select Parkinson's patients.
- The dose dispenser system demonstrated user-friendliness and high adherence.
- Larger, prospective studies are required to validate these preliminary findings.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:20Gastrointestinal Motility Disorders
1.4K
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
1.4K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.5K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.5K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
809
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
809
01:15Drug Dosing: Geriatric Patients
328
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
328